Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease.

Shiro Kitamoto, Kensuke Egashira

    研究成果: Contribution to journalReview article査読

    21 被引用数 (Scopus)


    Monocyte chemoattractant protein-1 (MCP-1) has been shown to play an essential role in the pathogenesis of arteriosclerosis and other vascular diseases, such as restenosis after arterial injury, by recruiting monocytes into the arterial wall. We devised a new strategy for anti-MCP-1 gene therapy against arteriosclerosis by transfecting an amino-terminal deletion mutant (7ND), which lacks the amino-terminal amino acids 2 to 8 of the human MCP-1 gene, into a remote organ (skeletal muscles). Intramuscular transduction with the mutant MCP-1 gene suppressed inflammatory and proliferative changes and arteriosclerosis formation induced by the chronic inhibition of nitric oxide synthesis in rats. 7ND gene transfection also inhibited the initiation, progression, and destabilization of atherosclerosis in Apolipoprotein E-knockout mice. Moreover, the strategy reduced restenosis after balloon injury in rabbits, rats, and monkeys, or neointimal formation after stent implantation in monkeys. This new strategy may be a useful and feasible gene therapy against atherosclerosis and restenosis after angioplasty.

    ジャーナルJournal of atherosclerosis and thrombosis
    出版ステータス出版済み - 2002

    All Science Journal Classification (ASJC) codes

    • 内科学
    • 循環器および心血管医学
    • 生化学、医学


    「Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease.」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。